Summary. In 17 patients with compensated autonomous adenomas of the thyroid, iv thyrotropin releasing hormone (TRH) tests (200 pg) and oral TRH tests (40 rag) were performed. In nine of these patients, thyroid-stimulating hormone (TSH) 30 min after iv TRH showed a normal (>2.7 ~U/ml) and in eight patients a subnormal (<2.7 gU/ml) or negative response. However, after prolonged oral stimulation with 40 mg TRH, after 120-180 rain TSH was normal (>2.7 laU/ml) in 15 and subnormal ( <2.7 pU/ml) in two patients.
Introduction
Patients with scintigraphically decompensated autonomous thyroid nodules usually reveal negative intravenous 200 gg TRH tests [3] .
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However. surprisingly comparable test results have been obtained in about 30% of patients with scintigraphically compensated autonomous adenomas [2] . Therefore, diagnosis of compensated and decompensated autonomous thyroid nodules is based primarily on scintigraphic findings and only to a small extent on the results of in vitro parameters of thyroid function. However, the oral TRH stimulation test was introduced recently and has been believed to be useful in the evaluation of patients with impaired TSH reserve but euthyroid function [I. 4, 5] . In these studies, about 10%-12% of apparently euthyroid patients revealed negative intravenous 200 lag TRH tests. In 50%-60% of these patients, autonomous production of thyroid hormones could be excluded by the 40-rag oral TRH test. It was the aim of this study to evaluate whether the oral TRH test is superior to the iv TRH test in the discrimination of compensated and decompensated autonomous adenomas classified by nuclear imaging.
Materials and Methods
The study included a total of 37 outpatients (12 males and 25 females) with an age ranging from 30 to 82 years. Diagnosis of autonomous thyroid nodules was based on the results of nuclear imaging with 99~Tc-pertechnate (employing a 20% uptake of the paranodular tissue as the discriminating value), including scintigraphy, after suppression with 60 gg T3 tbr 10 days in cases suspected to have compensated autonomous adenomas. In all patients, intravenous TRH tests were performed after an overnight fasting period with a boluslike injection of 200 gg TRH and TSH-RIA (Henning, Berlin), 30 rain aRer TRH application. For oral TRH tests, a 40 mg tablet of TRH (Thyroliberin, Merck, FRG) was used and single TSH determinations were done after 120-180 min. There was an interval of 2-6 weeks between the iv and oral TRH tests. T4 was measured by enzyme immunoassay (Syva Company, Palo Alto, USA) and T 3 by radio immunoassay (Amersham-Buchler, Braunschweig, FRG).
Results
In 17 patients (5 males and 12 females), scintigraphy after suppression revealed a formerly compensated autonomous adenoma. Concentrations of thyroid hormones were measured prior to appIication ofT~. T 4 (5.4-10.8 ~tg/dl, 2=7.4 pg/dl) and T3 (1.0-2.9 ng/ml, 2,:: 1.9 ng/ml) concentrations in plasma were mainly in the normal range.
Thyroid-stimulating hormone, 30 min after 200 gg iv TRH (0.8-14.6 gU/ml, 2=2.7 laU/ml), showed in nine patients a normal (>2.7 btU/ml) and in eight patients a subnormal (<2.7 laU/ml) or negative response. However, TSH 120-180 min after 40 mg orat TRH was normal (>2.7 laU/ml) in 15 patients and subnormal (<2.7 gU/mt) in only two patients.
In 20 patients (7 males and 13 females) scintigraphy demonstrated a primarily decompensated autonomous adenoma. In such cases, 30%-40% of T, (4.0-14.6gg/dl, 2=7.8~tg/dl) and T a (1,6 4.3 ng/ml, ~7=2.3 ng/ml) values were elevated. Thirty minutes after 200 gg iv TRH and 120-180 rain after 40 mg oral TRH, TSH was not detectable (<0.8 laU/ml) in all cases in accordance with the scintigraphic findings of decompensated autonomous thyroid nodules.
Discussion
Patients with scintigraphically decompensated autonomous thyroid nodules usually reveal negative iv 200 lag TRH tests. These data could be confirmed in the present study.
Nearly 50% of the 17 patients with scintigraphically compensated autonomous thyroid nodules revealed a subnormal or negative response to iv TRH in accordance with prior studies [2] . However, prolonged stimulation with 40 mg oral TRH in these patients was associated with normal TSH response in 15 (88%) and subnormal in two (12%). All patients with decompensated autonomous thyroid nodules showed a failing TSH response to iv TRH and even to prolonged oral TRH stimulation.
These findings point to a possible clinical validity of the oral TRH test as a help in the differentiation of compensated and decompensated autonomous adenomas, especially in borderline cases. In addition, in patients scintigraphically suspected to have compensated thyroid nodules, a negative result of an oral TRH test may help to exclude this diagnosis and prevent further diagnostic procedures, e.g., the T3-suppression-test.
